top of page
Asset 1@3x.png

Pioneering the development of novel immunotherapies for patients with blood cancers and B-cell disorders.

News & Events

HaemaLogiX is pleased to announce that our Chief Manufacturing and Development Officer, Tertia Dex, has been invited to speak at the 2nd Annual Australia Biologics Festival #ABF 2024 held February 20-21 in Melbourne.

HaemaLogiX’s CMDO Tertia Dex to speak at 2nd Australia Biologics Festival 2024

20 November 2023
HaemaLogiX Ltd, a clinical stage Australian biotech, is pleased to announce the appointment of Damian Clarke-Bruce as Managing Director and CEO, effective 13 November 2023.

HaemaLogiX Announces Appointment of Damian Clarke-Bruce as Managing Director and CEO

13 November 2023
 HaemaLogiX announces issuance of Israeli patent for KMA.CAR-T

HaemaLogiX announces issuance of Israeli patent for KMA.CAR-T

30 October 2023

Our Team

The HaemaLogiX management team has deep expertise in immunotherapy development and the unique antigens that our treatments target. Our Scientific Advisory Board comprises internationally recognised experts in monoclonal antibodies and haematology. 

Asset3@3x.png
Asset 4@3x.png

Our Pipeline

We’re developing a suite of diverse immunotherapies including monoclonal antibodies, CAR-T cells and bispecific antibodies, with a key focus on treating multiple myeloma and early investigation of AL Amyloidosis. 

Our Innovation

Our immunotherapies are designed to target and attack two unique antigens expressed on malignant cells – these antigens are not found on normal cells or tissues - making our treatments unlike others on the market. 

car-t ell.png
bottom of page